Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition with kidney protection function in chronic cardiac failure (CHF)

A chronic heart failure and composition technology, applied in the field of medicine, can solve the problem of expensive relaxin and achieve the effect of protecting kidney function

Inactive Publication Date: 2017-11-10
THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, relaxin is expensive, and it is necessary to consider drug combination therapy to reduce the amount of relaxin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition with kidney protection function in chronic cardiac failure (CHF)
  • Pharmaceutical composition with kidney protection function in chronic cardiac failure (CHF)
  • Pharmaceutical composition with kidney protection function in chronic cardiac failure (CHF)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The present invention will be further described in detail below in conjunction with the embodiments and the accompanying drawings, but the embodiments of the present invention are not limited thereto.

[0023] The invention confirms the kidney protection effect of the pharmaceutical composition composed of spironolactone and relaxin in chronic heart failure through experiments.

[0024] 1. The pharmaceutical composition composed of spironolactone and relaxin protects heart function, and the effect is better than that of monotherapy.

[0025] (1) The present invention utilizes isoproterenol to establish an animal model of cardiac fibrosis in chronic heart failure.

[0026] (2) Animal grouping: the present invention selects 50 male SD rats and randomly divides them into 5 groups after one week of adaptive feeding: control group, model group, spironolactone group, relaxin group and combined treatment group.

[0027] (3) Cardiac function evaluation of each group: In the pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses pharmaceutical composition with a kidney protection function in chronic cardiac failure (CHF). The pharmaceutical composition is prepared from antisterone and relaxin in the mass ratio being 15,000:1 through mixing. The kidney protection function of antisterone and relaxin in CHF is determined, research results indicate that in a model with myocardial fibrosis, the combination scheme significantly improves the cardiac function, cardiac hypertrophy and fibrosis, protects the kidney and has the effect superior to that of single medicine treatment. CRS (cardio-renal syndrome), this is, when injury of the heart or kidney to another organ cannot be compensated, they interact as both causes and effects, vicious cycle is formed, and joint injury and failure of heart and kidney functions are finally accelerated. The CHF is accompanied with renal injury, therefore, the pharmaceutical composition prepared from antisterone and relaxin through mixing provides a new idea for kidney protection in CHF.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for protecting renal function of chronic heart failure. Background technique [0002] Chronic heart failure (CHF) is the final stage of many cardiovascular diseases such as myocardial infarction, cardiomyopathy, hypertensive heart disease, and the occurrence of heart failure is related to the gradual fibrosis of the heart. Myocardial fibrosis refers to excessive accumulation of collagen fibers in the normal tissue structure of the myocardium, a significant increase in collagen concentration and collagen volume fraction in cardiac tissue, or changes in collagen composition. Collagen fibers reduce the compliance of the ventricular wall, increase stiffness, and limit diastolic filling; fibrosis of the coronary artery makes the wall thicker, the lumen is narrowed, the elasticity is reduced, and the blood supply of myocardial cells is reduced; myocardial cell necro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/22A61P9/04A61P13/12A61K31/585
CPCA61K31/585A61K38/2221A61K2300/00
Inventor 周浩
Owner THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV